Pseudomonas aeruginosa is a gram negative bacillus that colonizes in moist environment of the hospital settings with occurrence of antimicrobial resistance. Increasing resistance to beta-lactam drugs, especially the 3rd-generation cephalosporins, in Pseudomonas aeruginosa is predominantly due to the production of extended spectrum beta-lactamases (ESBLs). This was a laboratory based observational study carried out over a period of 7 months from April 2019 to December 2019. A total of 207 pus samples from different patient sources of the hospital were collected and processed in the microbiology laboratory. Among these samples, positive clinical isolates of Pseudomonas aeruginosa were recovered. Next, ESBL production in all these isolates was detected by using double disc synergy test (DDST). P. aeruginosa were also tested against different antibiotics for determination of the antibiogram of these isolates. Out of 207 pus samples, 45 (21.7%) clinical isolates of P. aeruginosa were detected. Out of these, 26.6 % of the P. aeruginosa isolates (n=12) were confirmed to be ESBL producers by the DDST method and rest 73.3%were non-ESBL producer (n=33). Our results showed that the ESBL strains were multi-drug resistant but colistin sensitive. Our results show that one-fourth of P. Aeruginosa clinical isolates express ESBLs; and were resistant to commonly used antibiotics inclusive of some beta-lactams and non-beta-lactam antibiotics. There is therefore need for proper monitoring and detection of the ESBL strain for guiding suitable therapy and to contain their nefarious effect on antibiotics.

Download this article as